Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib plus platinum chemotherapy and local therapy for EGFR-mutant stage III-N3 NSCLC
ChiCTR2400093459Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib, cisplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
almonertinibcisplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400093459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093459.